Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 6Plasma cell 1Myeloid 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 444Neoplasms, Plasma Cell 77Recurrence 62Lymphoma 52Lymphoma, Non-Hodgkin 48Leukemia 43Hodgkin Disease 43Leukemia, Myeloid, Acute 42Myelodysplastic Syndromes 37Leukemia, Lymphocytic, Chronic, B-Cell 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Lymphoma, Mantle-Cell 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 27Hematologic Neoplasms 24Burkitt Lymphoma 24Immunoglobulin Light-chain Amyloidosis 22Myeloproliferative Disorders 21Lymphoma, B-Cell, Marginal Zone 21Waldenstrom Macroglobulinemia 18Lymphoma, Large-Cell, Immunoblastic 18Neoplasms 17Lymphoma, T-Cell, Cutaneous 16Lymphoma, Large-Cell, Anaplastic 14Leukemia, Myelomonocytic, Chronic 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Sezary Syndrome 13Mycosis Fungoides 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myeloid, Accelerated Phase 12

Interventions

KW-2478 1Hsp90 inhibitor KU757 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bronchiolitis Obliterans Syndrome × Plasma cell × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡